Sweden-based AAX Biotech revealed that Maria Lisa Knudsen has been appointed as chief executive of the company. Dr Knudsen has a broad international experience in research and business development.
Having obtained a PhD in infection biology from the Karolinska Institutet, she conducted extensive research at renowned institutions in the USA and Singapore. Subsequently, she made a transition to the role of business development director at Salipro Biotech in Sweden, where Dr Knudsen was involved in out-licensing the company’s technology platform for drug discovery as well as establishing an internal pipeline.
“We are thrilled to have Maria join the team as we strengthen our IP portfolio and build partnerships with biotech and pharma companies. Maria’s combined experience in antibody research and business development will be instrumental for advancing AAX Biotech’s cutting-edge technologies for antibody therapeutics,” says Daniel Johansson, co-founder and chief scientific officer of AAX Biotech.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze